je.st
news
Celgene Upgraded By Credit Suisse, Market Shrugs; More Biotech Upside Ahead?
2013-12-11 13:26:51| Biotech - Topix.net
We are raising 2017 total sales and EPS to $13B and $16.00 . The largest change to our model is an increase in Revlimid sales to $7.6B due to lengthening of treatment duration and increasing penetration in the first-line setting following positive MM-020 presented over the weekend at the ASH Meeting.
Tags: market
credit
ahead
suisse
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||